AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

FMS-like tyrosine kinase 3 (FLT3) mutations represent some of the most pivotal genetic alterations in acute myeloid leukemia (AML), influencing ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem ...

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor ... chimeric antigen receptor (CAR) T-cell ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

who have the relatively rare human epidermal growth factor receptor 2 (HER2)- mutations within the tyrosine kinase domain (TKD). At this year’s American Association for Cancer Research (AACR ...

The oral HER2 inhibitor zongertinib benefited patients with previously treated, HER2-mutated non-small cell lung cancer in a phase I clinical trial, according to results presented by John V. Heymach, ...